Slideshows Images Quizzes

Copyright © 2018 by RxList Inc. RxList does not provide medical advice, diagnosis or treatment. See additional information.

Lexiscan

Last reviewed on RxList: 9/17/2018
Lexiscan Side Effects Center

Last reviewed on RxList 9/17/2018

Lexiscan (regadenoson) injection is a stress agent that works by increasing blood flow in the arteries of the heart given in preparation for a radiologic (x-ray) examination of blood flow through the heart to test for coronary artery disease. Common side effects of Lexiscan include:

  • headache,
  • dizziness,
  • nausea,
  • stomach discomfort,
  • decreased sense of taste,
  • mild chest discomfort,
  • shortness of breath, or
  • flushing (warmth, redness, or tingly feeling under your skin).

The recommended intravenous dose of Lexiscan is 5 mL, administered as a rapid (approximately 10 seconds) injection into a peripheral vein. Lexiscan may interact with dipyridamole or theophylline. Tell your doctor all medications you use. During pregnancy, Lexiscan should be used only if prescribed. It is unknown if this drug passes into breast milk or if it could harm a nursing baby. Consult your doctor before breastfeeding.

Our Lexiscan (regadenoson) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

SLIDESHOW

Health Screening Tests Every Woman Needs See Slideshow
Lexiscan Consumer Information

Get emergency medical help if you have signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.

Tell your caregiver right away if you have:

  • severe dizziness, fast heartbeats, and warmth or a tingly feeling;
  • wheezing, chest tightness, trouble breathing;
  • weak or shallow breathing;
  • chest pain or pressure, pain spreading to your jaw or shoulder;
  • a seizure;
  • low blood pressure--a light-headed feeling, like you might pass out;
  • high blood pressure--a severe headache or pounding in your neck or ears;
  • signs of a stroke--sudden numbness or weakness (especially on one side of the body), severe headache, slurred speech, balance problems.

Common side effects may include:

  • trouble breathing;
  • headache, dizziness;
  • chest pain or discomfort;
  • nausea; or
  • flushing (warmth, redness, or tingly feeling).

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1 800 FDA 1088.

Read the entire detailed patient monograph for Lexiscan (Regadenoson Injection)

Lexiscan Professional Information

SIDE EFFECTS

The following adverse reactions are discussed in more detail in other sections of the labeling.

  • Myocardial Ischemia [see WARNINGS AND PRECAUTIONS]
  • Sinoatrial and Atrioventricular Nodal Block [see WARNINGS AND PRECAUTIONS]
  • Atrial Fibrillation/Atrial Flutter [see WARNINGS AND PRECAUTIONS]
  • Hypersensitivity, Including Anaphylaxis [see WARNINGS AND PRECAUTIONS]
  • Hypotension [see WARNINGS AND PRECAUTIONS]
  • Hypertension [see WARNINGS AND PRECAUTIONS]
  • Bronchoconstriction [see WARNINGS AND PRECAUTIONS]
  • Seizure [see WARNINGS AND PRECAUTIONS]
  • Cerebrovascular Accident (Stroke) [see WARNINGS AND PRECAUTIONS]

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

During clinical development, 1,651 patients were exposed to LEXISCAN, with most receiving 0.4 mg as a rapid (≤ 10 seconds) intravenous injection. Most of these patients received LEXISCAN in two clinical studies that enrolled patients who had no history of bronchospastic lung disease as well as no history of a cardiac conduction block of greater than first-degree AV block, except for patients with functioning artificial pacemakers. In these studies (Studies 1 and 2), 2,015 patients underwent myocardial perfusion imaging after administration of LEXISCAN (N = 1,337) or ADENOSCAN(N = 678). The population was 26–93 years of age (median 66 years), 70% male and primarily Caucasian (76% Caucasian, 7% African American, 9% Hispanic, 5% Asian). Table 1 shows the most frequently reported adverse reactions.

Overall, any adverse reaction occurred at similar rates between the study groups (80% for the LEXISCAN group and 83% for the ADENOSCAN group). Aminophylline was used to treat the reactions in 3% of patients in the LEXISCAN group and 2% of patients in the ADENOSCAN group. Most adverse reactions began soon after dosing, and generally resolved within approximately 15 minutes, except for headache which resolved in most patients within 30 minutes.

Table 1- Adverse Reactions in Studies 1 and 2 Pooled (Frequency ≥ 5%)

  LEXISCAN
N = 1,337
ADENOSCAN
N = 678
Dyspnea 28% 26%
Headache 26% 17%
Flushing 16% 25%
Chest Discomfort 13% 18%
Angina Pectoris or ST Segment Depression 12% 18%
Dizziness 8% 7%
Chest Pain 7% 10%
Nausea 6% 6%
Abdominal Discomfort 5% 2%
Dysgeusia 5% 7%
Feeling Hot 5% 8%

ECG Abnormalities

The frequency of rhythm or conduction abnormalities following LEXISCAN or ADENOSCAN is shown in Table 2 [see WARNINGS AND PRECAUTIONS].

Table 2 - Rhythm or Conduction Abnormalities* in Studies 1 and 2

  LEXISCAN
N / N evaluable (%)
ADENOSCAN
N / N evaluable (%)
Rhythm or conduction abnormalities 332/1275 (26%) 192/645 (30%)
Rhythm abnormalities 260/1275 (20%) 131/645 (20%)
PACs 86/1274 (7%) 57/645 (9%)
PVCs 179/1274 (14%) 79/645 (12%)
First-degree AV block (PR prolongation > 220 msec) 34/1209 (3%) 43/618 (7%)
Second-degree AV block 1/1209 (0.1%) 9/618 (1%)
AV conduction abnormalities (other than AV blocks) 1/1209 (0.1%) 0/618 (0%)
Ventricular conduction abnormalities 64/1152 (6%) 31/581 (5%)
*12-lead ECGs were recorded before and for up to 2 hours after dosing.
includes rhythm abnormalities (PACs, PVCs, atrial fibrillation/flutter, wandering atrial pacemaker, supraventricular or ventricular arrhythmia) or conduction abnormalities, including AV block.

Respiratory Abnormalities

In a randomized, placebo-controlled trial of 999 patients with asthma (n = 532) or stable chronic obstructive pulmonary disease (n = 467), the overall incidence of pre-specified respiratory adverse reactions was greater in the LEXISCAN group compared to the placebo group (p < 0.001). Most respiratory adverse reactions resolved without therapy; a few patients received aminophylline or a short-acting bronchodilator. No differences were observed between treatment arms in the reduction of >15% from baseline at two-hours in FEV1 (Table 3).

Table 3 - Respiratory Adverse Effects*

  Asthma Cohort Chronic Obstructive Pulmonary Disease (COPD) Cohort
LEXISCAN
(N=356)
Placebo
(N=176)
LEXISCAN
(N=316)
Placebo
(N=151)
Overall Pre-specified Respiratory Adverse Reaction 12.9% 2.3% 19.0% 4.0%
  Dyspnea 10.7% 1.1% 18.0% 2.6%
  Wheezing 3.1% 1.1% 0.9% 0.7%
FEV1 reduction >15% 1.1% 2.9% 4.2% 5.4%
*All patients continued the use of their respiratory medications as prescribed prior to administration of LEXISCAN.
Patients may have reported more than one type of adverse reaction. Adverse reactions were collected up to 24 hours following drug administration. Pre-specified respiratory adverse reactions included dyspnea, wheezing, obstructive airway disorder, dyspnea exertional, and tachypnea.
Change from baseline at 2 hours.

Renal Impairment

In a randomized, placebo-controlled trial of 504 patients (LEXISCAN n=334 and placebo n=170) with a diagnosis or risk factors for coronary artery disease and NKFK/DOQI Stage III or IV renal impairment (defined as GFR 15-59 mL/min/1.73 m2), no serious adverse events were reported through the 24-hour follow-up period.

Inadequate Exercise Stress

In an open-label, multi-center trial evaluating LEXISCAN administration following inadequate exercise stress, 1,147 patients were randomized into one of two groups. Each group underwent two LEXISCAN stress myocardial perfusion imaging (MPI) procedures. Group 1 received LEXISCAN 3 minutes following inadequate exercise in the first LEXISCAN stress (MPI 1). Group 2 rested 1 hour after inadequate exercise to allow hemodynamics to return to baseline prior to receiving LEXISCAN (MPI 1). Both groups returned for a second stress MPI 1-14 days later and received LEXISCAN without exercise (MPI 2).

The most common adverse reactions are similar in type and incidence to those in Table 1 above for both Groups. The timing of the administration of LEXISCAN following inadequate exercise did not alter the common adverse reaction profile.

Table 4 shows a comparison of cardiac events of interest for the two groups [see WARNINGS AND PRECAUTIONS]. The cardiac events were numerically higher in Group 1.

Table 4 - Cardiac Events of Interest in Inadequate Exercise Stress Study

  Group 1 / MPI 1
LEXISCAN 3 minutes following exercise
(N=575)
Group 2 / MPI 1
LEXISCAN 1 hour following exercise
(N=567)
Cardiac Event* 17 (3.0%) 3 (0.5%)
Holter/12-Lead ECG Abnormality    
  ST-T Depression (≥ 2 mm) 13 (2.3%) 2 (0.4%)
  ST-T Elevation (≥ 1 mm) 3 (0.5%) 1 (0.2%)
Acute coronary syndrome 1 (0.2%) 0
Myocardial infarction 1 (0.2%) 0
*A clinically significant cardiac event was defined as any of the following events found on the Holter ECG/12-lead ECG within one hour after regadenoson administration: ventricular arrhythmias (sustained ventricular tachycardia, ventricular fibrillation, Torsade de Pointes, ventricular flutter); ST-T depression (≥ 2 mm); ST-T elevation (≥ 1 mm); AV block (2:1 AV block, AV Mobitz I, AV Mobitz II, complete heart block); sinus arrest > 3 seconds in duration
Or
  • a Treatment Emergent Adverse Event (TEAE) per the MedDRA SMQ (narrow Scope) for myocardial infarction
Or
  • a TEAE preferred term (PT) of angina unstable within 24 hours of regadenoson administration.

Post-Marketing Experience

The following adverse reactions have been reported from worldwide marketing experience with regadenoson. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Cardiovascular

Myocardial infarction, cardiac arrest, ventricular arrhythmias, supraventricular tachyarrhythmias including atrial fibrillation with rapid ventricular response (new-onset or recurrent), atrial flutter, heart block (including third-degree block), asystole, marked hypertension, symptomatic hypotension in association with transient ischemic attack, acute coronary syndrome (ACS), seizures and syncope [see WARNINGS AND PRECAUTIONS] have been reported. Some events required intervention with fluids and/or aminophylline [see OVERDOSE]. QTc prolongation shortly after LEXISCAN administration has been reported.

Central Nervous System

Tremor, seizure, transient ischemic attack, and cerebrovascular accident including intracranial hemorrhage [see WARNINGS AND PRECAUTIONS].

Gastrointestinal

Abdominal pain, occasionally severe, has been reported a few minutes after LEXISCAN administration, in association with nausea, vomiting, or myalgias; administration of aminophylline, an adenosine antagonist, appeared to lessen the pain. Diarrhea and fecal incontinence have also been reported following LEXISCAN administration.

Hypersensitivity

Anaphylaxis, angioedema, cardiac or respiratory arrest, respiratory distress, decreased oxygen saturation, hypotension, throat tightness, urticaria, rashes have occurred and have required treatment including resuscitation [see WARNINGS AND PRECAUTIONS].

Musculoskeletal

Musculoskeletal pain has occurred, typically 10-20 minutes after LEXISCAN administration; the pain was occasionally severe, localized in the arms and lower back and extended to the buttocks and lower legs bilaterally. Administration of aminophylline appeared to lessen the pain.

Respiratory

Respiratory arrest, dyspnea and wheezing have been reported following LEXISCAN administration.

Read the entire FDA prescribing information for Lexiscan (Regadenoson Injection)

Related Resources for Lexiscan

© Lexiscan Patient Information is supplied by Cerner Multum, Inc. and Lexiscan Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.

SLIDESHOW

Health Screening Tests Every Woman Needs See Slideshow

Health Solutions From Our Sponsors

CONTINUE SCROLLING FOR RELATED SLIDESHOW